JP2011500582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500582A5 JP2011500582A5 JP2010529007A JP2010529007A JP2011500582A5 JP 2011500582 A5 JP2011500582 A5 JP 2011500582A5 JP 2010529007 A JP2010529007 A JP 2010529007A JP 2010529007 A JP2010529007 A JP 2010529007A JP 2011500582 A5 JP2011500582 A5 JP 2011500582A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- treatment cycle
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97959407P | 2007-10-12 | 2007-10-12 | |
| US60/979,594 | 2007-10-12 | ||
| US2766808P | 2008-02-11 | 2008-02-11 | |
| US61/027,668 | 2008-02-11 | ||
| US4064108P | 2008-03-28 | 2008-03-28 | |
| US61/040,641 | 2008-03-28 | ||
| PCT/US2008/079224 WO2009048967A1 (en) | 2007-10-12 | 2008-10-08 | Combination therapy with antibody-drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500582A JP2011500582A (ja) | 2011-01-06 |
| JP2011500582A5 true JP2011500582A5 (enExample) | 2011-11-10 |
| JP5485897B2 JP5485897B2 (ja) | 2014-05-07 |
Family
ID=40549535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529007A Expired - Fee Related JP5485897B2 (ja) | 2007-10-12 | 2008-10-08 | 抗体−薬物複合体の併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8263083B2 (enExample) |
| EP (1) | EP2211885B1 (enExample) |
| JP (1) | JP5485897B2 (enExample) |
| KR (1) | KR101641345B1 (enExample) |
| CN (1) | CN101969970B (enExample) |
| AU (1) | AU2008310908B2 (enExample) |
| CA (1) | CA2699090C (enExample) |
| EA (1) | EA020696B1 (enExample) |
| IL (1) | IL204851A (enExample) |
| MX (1) | MX2010003977A (enExample) |
| NZ (1) | NZ584552A (enExample) |
| WO (1) | WO2009048967A1 (enExample) |
| ZA (1) | ZA201002428B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| MY150531A (en) | 2007-07-16 | 2014-01-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| AU2008310908B2 (en) | 2007-10-12 | 2014-01-09 | Seagen Inc. | Combination therapy with antibody-drug conjugates |
| DK2657253T3 (en) | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
| CA3150199C (en) | 2009-01-09 | 2025-07-22 | Seagen Inc | WEEKLY DOSING REGIMEN FOR ANTI-CD30 ANTIBODY CONJUGATIONS VC-PAB-MMAE - MEDICINE |
| US8758758B1 (en) * | 2010-01-08 | 2014-06-24 | Seattle Genetics, Inc. | Post-relapse treatment of CD30 expressing lymphomas |
| UA115517C2 (uk) * | 2010-02-08 | 2017-11-27 | Ейдженсіс, Інк. | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b |
| ES3004351T3 (en) | 2010-10-22 | 2025-03-12 | Seagen Inc | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| ES2708699T3 (es) * | 2011-09-29 | 2019-04-10 | Seattle Genetics Inc | Determinación de la masa intacta de compuestos de agentes conjugados con proteínas |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| PT3327027T (pt) | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
| EP2812702B1 (en) * | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
| BR112015010436A2 (pt) | 2012-11-07 | 2017-08-22 | Pfizer | Anticorpos anti-notch3 e conjugados anticorpo-fármaco |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| DK3262071T3 (da) | 2014-09-23 | 2020-06-15 | Hoffmann La Roche | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater |
| EP3223854A1 (en) | 2014-11-25 | 2017-10-04 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| MX2020003664A (es) * | 2017-10-11 | 2020-10-12 | Seattle Genetics Inc | Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco. |
| CA3077729A1 (en) * | 2017-10-13 | 2019-04-18 | Seattle Genetics, Inc. | Modulating the immune response using antibody-drug conjugates |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| KR20210006362A (ko) * | 2018-04-06 | 2021-01-18 | 시애틀 지네틱스, 인크. | 캄토테신 펩타이드 접합체들 |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| TW202519270A (zh) | 2018-06-07 | 2025-05-16 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| WO2020127618A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic cd28 antigen binding molecules |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| CA3152316A1 (en) * | 2019-10-04 | 2021-04-08 | Scott C. Jeffrey | Camptothecin peptide conjugates |
| JP2023512084A (ja) * | 2020-01-31 | 2023-03-23 | シージェン インコーポレイテッド | 抗ｃｄ３０抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用 |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| CN119490595B (zh) * | 2023-08-15 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗免疫球蛋白e的抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5165922A (en) * | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| PT3248613T (pt) * | 2005-07-18 | 2022-03-16 | Seagen Inc | Conjugados de ligante de fármaco e beta-glucuronida |
| CA2625998C (en) * | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008025020A2 (en) * | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
| WO2008103916A2 (en) | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia Univeristy In The City Of New York | Compositions and methods for treating cancer or a neurotrophic disorder |
| AU2008310908B2 (en) | 2007-10-12 | 2014-01-09 | Seagen Inc. | Combination therapy with antibody-drug conjugates |
-
2008
- 2008-10-08 AU AU2008310908A patent/AU2008310908B2/en active Active
- 2008-10-08 EP EP08837451.7A patent/EP2211885B1/en active Active
- 2008-10-08 EA EA201070463A patent/EA020696B1/ru unknown
- 2008-10-08 NZ NZ584552A patent/NZ584552A/en unknown
- 2008-10-08 WO PCT/US2008/079224 patent/WO2009048967A1/en not_active Ceased
- 2008-10-08 MX MX2010003977A patent/MX2010003977A/es active IP Right Grant
- 2008-10-08 JP JP2010529007A patent/JP5485897B2/ja not_active Expired - Fee Related
- 2008-10-08 KR KR1020107008660A patent/KR101641345B1/ko active Active
- 2008-10-08 CA CA2699090A patent/CA2699090C/en active Active
- 2008-10-08 CN CN200880111297.1A patent/CN101969970B/zh active Active
- 2008-10-08 US US12/681,599 patent/US8263083B2/en active Active
-
2010
- 2010-04-06 IL IL204851A patent/IL204851A/en active IP Right Grant
- 2010-04-07 ZA ZA2010/02428A patent/ZA201002428B/en unknown
-
2012
- 2012-08-13 US US13/571,313 patent/US8470329B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500582A5 (enExample) | ||
| Chu et al. | Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis | |
| Mahalingaiah et al. | Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates | |
| Hedrich et al. | Antibody–drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned | |
| CN111587124B (zh) | Ror1抗体免疫缀合物 | |
| JP6297550B2 (ja) | 抗ｃｄ７９ｂ抗体を含む免疫複合体 | |
| Mack et al. | The next generation of antibody drug conjugates | |
| NZ707543A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| WO2007100385A3 (en) | Macrocyclic depsipeptide antibody-drug conjugates and methods | |
| JP2011508738A5 (enExample) | ||
| Drachman et al. | Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer | |
| WO2004050705A3 (en) | Complexes of receptors | |
| WO2007134037A3 (en) | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments | |
| JP2016183182A5 (enExample) | ||
| JP2017537893A5 (enExample) | ||
| EP1732602A4 (en) | CYTOTOXIC MEDIATION OF CELLS WITH SUPERFICIAL EXPRESSION OF MCSP | |
| NZ707534A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| JP2015531750A5 (enExample) | ||
| WO2010091192A2 (en) | Nanoscale platinum compounds and methods of use thereof | |
| WO2015057250A1 (en) | Combination therapies with psma ligand conjugates | |
| JP2021505661A5 (enExample) | ||
| JP2006265245A5 (enExample) | ||
| GB2449044A (en) | Cytotoxicity mediation of cells evidencing surface expression of cd63 | |
| Vassilakopoulos et al. | Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years | |
| EP3057614A1 (en) | Combination therapies with psma ligand conjugates |